Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 5/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 5/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 5/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 5/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 15/20 | 0.80 |
| ▸ | PDGFRA | P16234 | 15/20 | 0.80 |
| ▸ | SRC | P12931 | 13/20 | 0.80 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
| ▸ | PRKCG | P05129 | 1/20 | 0.71 |
| ▸ | PRKCB | P05771 | 1/20 | 0.71 |
| ▸ | PRKCA | P17252 | 1/20 | 0.71 |
| ▸ | PRKCH | P24723 | 1/20 | 0.71 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | PRKCI | P41743 | 1/20 | 0.71 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.71 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.71 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8120559 | 0.89 | FGFR1 (1.00) | FGFR1EGFRFGFR2FGFR4FGFR3 | |
| SCHEMBL8127192 | 0.89 | FGFR1 (1.00) | FGFR1EGFRFGFR2FGFR4FGFR3 | |
| SCHEMBL8131429 | 0.84 | FGFR1 (1.00) | FGFR1EGFRFGFR2FGFR4FGFR3 | |
| SCHEMBL8123214 | 0.84 | FGFR1 (1.00) | FGFR1EGFRFGFR2FGFR4FGFR3 | |
| SCHEMBL8130155 | 0.83 | FGFR1 (1.00) | FGFR1EGFRFGFR2FGFR4FGFR3 | |
| SCHEMBL29382814 | 0.83 | FGFR1 (1.00) | FGFR1EGFRFGFR2FGFR4FGFR3 | |
| SCHEMBL8132023 | 0.83 | FGFR1 (1.00) | FGFR1EGFRFGFR2FGFR4FGFR3 | |
| SCHEMBL8129964 | 0.83 | FGFR1 (1.00) | FGFR1EGFRFGFR2FGFR4FGFR3 | |
| SCHEMBL8124128 | 0.83 | FGFR1 (1.00) | FGFR1EGFRFGFR2FGFR4FGFR3 | |
| SCHEMBL8132279 | 0.82 | FGFR1 (1.00) | FGFR1EGFRFGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0790997-B1 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2000-03-22 | — | — | EP | claimed |
| EP-0790997-A2 | 6-ARYL PYRIDO( 2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1997-08-27 | — | — | EP | claimed |
| WO-1996015128-A2 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | claimed |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-0790997-B1 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0790997-A2 | 6-ARYL PYRIDO( 2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015128-A2 | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | FGFR1 1/4885EGFR 475/4885FGFR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.